Brighter’s Actiste® Receives Telecommunication Approval in Qatar
Brighter AB (Publ.) announced today that the Qatari Communications Regulatory Authority has granted Actiste® type approval for the radio transmission element in the device. With this approval, both Actiste® (with insulin injection) and Actiste® Mini have now received telecom use approval in Qatar. On 18 February 2021, Brighter announced that the company had signed a five-year distribution agreement with Al Danah Medical Company in Qatar regarding Brighter’s pioneering product portfolio for diabetes management Actiste® (“Actiste Service”). “This approval is another significant